Literature DB >> 30336143

Voluntary exercise improves muscle function and does not exacerbate muscle and heart pathology in aged Duchenne muscular dystrophy mice.

Bauke Kogelman1, Kayleigh Putker2, Margriet Hulsker3, Christa Tanganyika-de Winter4, Louise van der Weerd5, Annemieke Aartsma-Rus6, Maaike van Putten7.   

Abstract

Duchenne muscular dystrophy is a severe muscle wasting disease, characterized by a severely reduced lifespan in which cardiomyopathy is one of the leading causes of death. Multiple therapies aiming at dystrophin restoration have been approved. It is anticipated that these therapies will maintain muscle function for longer and extend the ambulatory period, which in turn will increase the cardiac workload which could be detrimental for cardiac function. We investigated the effects of voluntary running exercise in combination with low dystrophin levels on function and pathology of skeletal muscle and heart. We divided 15.5-month old female mdx (no dystrophin), mdx-XistΔhs (varying low dystrophin levels) and wild type mice (BL10-WT and XistΔhs-WT) to either a sedentary or voluntary wheel running regime and assessed muscle function at 17.5 months of age. Thereafter, a cardiac MRI was obtained, and muscle and heart histopathology were assessed. We show that voluntary exercise is beneficial to skeletal muscle and heart function in dystrophic mice while not affecting muscle pathology. Low amounts of dystrophin further improve skeletal muscle and cardiac function. These findings suggest that voluntary exercise may be beneficial for skeletal muscle and heart in DMD patients, especially in conjunction with low amounts of dystrophin.
Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Cardiomyopathy; Exercise; Heart; Low dystrophin levels; Magnetic resonance imaging

Mesh:

Year:  2018        PMID: 30336143     DOI: 10.1016/j.yjmcc.2018.10.008

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  6 in total

1.  Current care practices for patients with Duchenne muscular dystrophy in China.

Authors:  Shu Zhang; Shaoxia Wang; Yuru Dong; Xinyu Chen; Miao Hu; Sen Kou; Chunyan Zhang; Shiwen Wu; Yaping Tian
Journal:  Brain Dev       Date:  2022-06-09       Impact factor: 2.272

2.  Moderate exercise improves function and increases adiponectin in the mdx mouse model of muscular dystrophy.

Authors:  Aaron S Zelikovich; Mattia Quattrocelli; Isabella M Salamone; Nancy L Kuntz; Elizabeth M McNally
Journal:  Sci Rep       Date:  2019-04-08       Impact factor: 4.379

3.  Uniform sarcolemmal dystrophin expression is required to prevent extracellular microRNA release and improve dystrophic pathology.

Authors:  Tirsa L E van Westering; Yulia Lomonosova; Anna M L Coenen-Stass; Corinne A Betts; Amarjit Bhomra; Margriet Hulsker; Lucy E Clark; Graham McClorey; Annemieke Aartsma-Rus; Maaike van Putten; Matthew J A Wood; Thomas C Roberts
Journal:  J Cachexia Sarcopenia Muscle       Date:  2019-12-17       Impact factor: 12.910

Review 4.  The new challenge of "exercise + X″ therapy for Duchenne muscular dystrophy-Individualized identification of exercise tolerance and precise implementation of exercise intervention.

Authors:  Yuhui Su; Yafeng Song
Journal:  Front Physiol       Date:  2022-08-05       Impact factor: 4.755

5.  Exercise protects proliferative muscle satellite cells against exhaustion via the Igfbp7-Akt-mTOR axis.

Authors:  Zhe Chen; Lei Li; Weiru Wu; Zhilong Liu; Yongxiu Huang; Li Yang; Qing Luo; Jieping Chen; Yu Hou; Guanbin Song
Journal:  Theranostics       Date:  2020-05-16       Impact factor: 11.556

6.  Evaluation of an exercise-enabling control interface for powered wheelchair users: a feasibility study with Duchenne muscular dystrophy.

Authors:  Joan Lobo-Prat; Aure Enkaoua; Antonio Rodríguez-Fernández; Nariman Sharifrazi; Julita Medina-Cantillo; Josep M Font-Llagunes; Carme Torras; David J Reinkensmeyer
Journal:  J Neuroeng Rehabil       Date:  2020-10-28       Impact factor: 4.262

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.